PowerUp Acquisition Corp. and Visiox Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form S-4 to the SEC in Connection with the Previously Announced Proposed Business Combination
Tarrytown, NY and New York, NY, Jan. 29, 2024 (GLOBE NEWSWIRE) — PowerUp Acquisition Corp. (“PowerUp”) (Nasdaq:PWUP) and Visiox Pharmaceuticals, Inc. (“Visiox”), a commercial-stage biopharmaceutical company, today announced that PowerUp has filed with the U.S. Securities and Exchange Commission (“SEC”) a registration statement on Form S-4 in connection with the previously announced proposed business combination between PowerUp and Visiox (the “Business Combination” or the “Transaction”).
Related news for (PWUP)
- aspire biopharma, inc., and powerup acquisition corp. announce business combination agreement to create nasdaq-listed biopharmaceutical company driving breakthrough innovations in fda approved drugs, nutraceuticals and supplements
- Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.